|
|
|
|
|
| April 30, 2009 | | Biotecnol successfully completes milestone of process development and manufacturing activities for Alligator Bioscience AB inflammation programme ADC -1004
| Read more>>
|  |
November 25, 2008 | Alligator Bioscience AB, the protein optimization company, to Present at the Rodman & Renshaw 10th Annual Healthcare Conference.
| | Read more >>
|  |
| June 16, 2008 | Alligator Bioscience AB and PolyTherics Ltd announce strategic collaboration for optimisation of next generation biopharmaceuticals
| | Read more >>
|  |
|
|
|
|
|
|
|
|
|
|
|
|
|
"We use our proprietary FIND® technology platform to discover and develop optimized protein drug candidates"
.... focusing on the treatment of Inflammation and Cancer"
|
|
|
|
|
|
|
|
|
|
|
|
|
ADC-1004 Protects Against
Inflammation Injury
Reperfusion injury is a serious complication after e.g. myocardial infarction treated with balloon dilatation. Alligator Bioscience has created a drug candidate, ADC-1004, that is assumed to protect against this reperfusion injury.
READ MORE ... |
|
 |
| |
|
|
|
|
ADC-1001 Second Generation IL-1Ra
Our FIND® technology has proven to be very useful in creating second generation biopharmaceuticals. Alligator Bioscience has made a second generation drug candidate of Anakinra (Kineret®) with increased receptor affinity compared to Anakinra.
READ MORE … |
|
 |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|